Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16521992 | 1.00 | HPGD (0.55) | HPGDMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL26478903 | 1.00 | HPGD (0.55) | HPGDMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL23020652 | 0.86 | HPGD (0.57) | HPGDMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL20879998 | 0.86 | HPGD (0.57) | HPGDMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL4817684 | 0.84 | HPGD (0.57) | HPGDMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL4817697 | 0.81 | HPGD (0.57) | HPGDMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL10353331 | 0.78 | TSHR (0.70) | HPGDMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL8321173 | 0.78 | TSHR (0.70) | HPGDMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL47623 | 0.77 | TSHR (0.43) | HPGDMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL47662 | 0.77 | TSHR (0.43) | HPGDMEN1KMT2ARECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-07-22 | — | — | US | disclosed |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | ASCENDIS PHARMA A/S (DK) | 2021-04-20 | — | — | US | disclosed |
| US-10960053-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-03-30 | — | — | US | disclosed |
| US-20200261544-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2020-08-20 | — | — | US | disclosed |
| US-10682395-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2020-06-16 | — | — | US | disclosed |
| US-20200046725-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2020-02-13 | — | — | US | disclosed |
| US-20190192634-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2019-06-27 | — | — | US | disclosed |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-07-05 | — | — | US | disclosed |
| US-9919033-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-03-20 | — | — | US | disclosed |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2017-04-13 | — | — | US | disclosed |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2017-03-02 | — | — | US | disclosed |
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | HPGD 28/4885MEN1 3163/4885KMT2A 4600/4885 |
| US-20200261544-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | HPGD 326/4885MEN1 402/4885KMT2A 1703/4885 |
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | HPGD 1998/4885MEN1 1323/4885KMT2A 327/4885 |
| US-10960053-B2 | PEGylated recombinant human growth hormone compounds | GHRHR, GHITM, GHSR | HPGD 650/4885MEN1 672/4885KMT2A 2937/4885 |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | HPGD 326/4885MEN1 402/4885KMT2A 1703/4885 |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | HPGD 1998/4885MEN1 1323/4885KMT2A 327/4885 |
| US-20190192634-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | HPGD 650/4885MEN1 672/4885KMT2A 2937/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | HPGD 21/4885MEN1 4821/4885KMT2A 3136/4885 |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | TNF, ADAMTS5, ADAMTS1 | HPGD 48/4885MEN1 1495/4885KMT2A 3627/4885 |
| US-20200046725-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | HPGD 2045/4885MEN1 1318/4885KMT2A 320/4885 |
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | HPGD 650/4885MEN1 672/4885KMT2A 2937/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | HPGD 21/4885MEN1 4821/4885KMT2A 3136/4885 |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | HPGD 326/4885MEN1 402/4885KMT2A 1703/4885 |
| US-10682395-B2 | Dry growth hormone composition transiently linked to a polymer carrier | GHRHR, GHSR, GCG | HPGD 326/4885MEN1 402/4885KMT2A 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.